EGFR mutation type(s) in CSF were largely concordant with those in the primary tumor (73.5% concordance for Huang and 90.9% concordance for Fan), proving that EGFR mutation testing in CSF from lung adenocarcinoma patients with CNS metastases is clinically feasible for guiding precision medicine. Here, EGFR is linked to lung adenocarcinoma.